TORONTO, ON / ACCESSWIRE / January 14, 2016 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSX-V: TLT) (OTC: TLTFF), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it will debut its next generation TLC-2000 Therapeutic Medical Laser System, at the Parker Seminar event in Las Vegas from January 14th to 16th, 2016.
The Parker Seminar, one of the world's largest chiropractic conferences, provides chiropractors with the opportunity to attend educational presentations presented by expert speakers and combine it with hands-on experience on the latest innovative medical technologies, to allow them to increase the effectiveness of their patient treatments and as a result grow their revenues.
Theralase, a proud sponsor of the event, will be performing product demonstrations of the TLC-2000 for the first time since receiving formal clearance from the US Food and Drug Administration and Health Canada in late 4Q2015.
The TLC-2000 is a next generation therapeutic laser that has the ability to heal a patient's injury faster and more effectively than any other technology on the market. Chiropractors attending the meeting will be able to test-drive the state-of-the-art system; including, it's ability to control 4 laser probes simultaneously to treat multiple locations on one or multiple patients, achieving higher efficiencies and better patient flow in their clinics.
Dr. James W. Gregg, a Canadian chiropractor and member of Theralase's Educational Board, will deliver a presentation entitled "Be the Go-To Chiropractor with Advanced Healing Technology" to attendees and share his personal clinical experience with the TLC-2000, at 10:30 am PST on Friday, January 15th, 2016.
Immediately following the seminar, Theralase will commence a dedicated marketing program in both Canada and the US aimed at promoting the benefits and advantages of the TLC-2000 technology over existing technologies to a wide range of healthcare practitioners; including, in-depth, private demonstrations of the technology in healthcare practitioners' offices located in Canada and the US.
Roger Dumoulin-White, President and CEO, stated that, "The Company has worked hard in 2015 to achieve regulatory approval for the next generation TLC-2000 and looks forward to introducing this revolutionary technology to healthcare practitioners in Canada and the US in 2016 to demonstrate what this next generation technology is capable of."
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
SOURCE: Theralase Technologies Inc.